Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTALYSE PE: Optimum Duration of Acoustic Pulse Thrombolysis for Submassive Pulmonary Embolism
2016-000502-11Phase 4Unknown
- Sponsor
- Boston Scientific Corporation
- Start
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tissue-plasminogen activator in pulmonary embolism (PE) (3 arms), sponsored by Boston Scientific Corporation. Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on 2016-000502-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000502-11.